sirolimus (QRX009) — Initial data
H2 2026
The Company plans to initiate proof of concept clinical testing in the second half of 2026 in at least one clinical indication.Source filing
QNRX biotech catalysts & pipeline
QUOIN PHARMACEUTICALS LTD · Data as of 2026-09-08
Upcoming catalysts
sirolimus (QRX009) — IND submission
Late 2026
Investigator-led studies are planned across several indications, including Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex, and the Company plans to submit an IND to the FDA for an additional indication before the end of 2026.Source filing
QRX003 — NDA/BLA submission
2027
- Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027Source filing
QRX003 — Topline data
Q2 2027
Quoin expects to complete recruitment of all 20 participants in CL-QRX003-004 by the end of 2026 and report topline data in the second quarter of 2027.Source filing